Makoto Yamagishi
Overview
Explore the profile of Makoto Yamagishi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jimbo K, Nojima M, Toriuchi K, Yamagishi M, Nakashima M, Yamano Y, et al.
Biomark Res
. 2025 Feb;
13(1):34.
PMID: 40012084
Background: Assessment of adult T-cell leukemia/lymphoma (ATL) development among human T-lymphotropic virus 1 (HTLV-1)-infected individuals (carriers) constitute a significant issue. A high HTLV-1 proviral load (PVL) in carriers has been...
2.
Mizuike J, Suzuki K, Tosaka S, Kuze Y, Kobayashi S, Nakashima M, et al.
Cancer Sci
. 2024 Nov;
116(2):513-523.
PMID: 39561277
Human T-cell leukemia virus type 1 (HTLV-1) broadly impacts host genes, affecting the infected cell population and inducing the development of a disease with a poor prognosis, adult T-cell leukemia-lymphoma...
3.
Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, et al.
Nature
. 2024 Feb;
627(8002):221-228.
PMID: 38383791
Epigenomes enable the rectification of disordered cancer gene expression, thereby providing new targets for pharmacological interventions. The clinical utility of targeting histone H3 lysine trimethylation (H3K27me3) as an epigenetic hallmark...
4.
Jimbo K, Yamagishi M, Suzuki Y, Suzuki K, Mizukami M, Yokoyama K, et al.
EJHaem
. 2023 Nov;
4(4):1188-1190.
PMID: 38024629
No abstract available.
5.
Koseki A, Araya N, Yamagishi M, Yamauchi J, Yagishita N, Takao N, et al.
Front Microbiol
. 2023 Jun;
14:1175762.
PMID: 37378292
Background: Human T-cell leukemia virus type 1 (HTLV-1) causes HTLV-1-associated myelopathy (HAM), adult T-cell leukemia/lymphoma (ATL), HTLV-1-associated uveitis, and pulmonary diseases. Although both HAM and ATL show proliferation of infected...
6.
Kobayashi-Ishihara M, Frazao Smutna K, Alonso F, Argilaguet J, Esteve-Codina A, Geiger K, et al.
Commun Biol
. 2023 May;
6(1):487.
PMID: 37165099
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen...
7.
Sato T, Yamauchi J, Yagishita N, Araya N, Takao N, Ohta Y, et al.
Brain
. 2023 Apr;
146(8):3181-3191.
PMID: 37093965
Some carriers of human T-cell leukaemia virus type 1 (HTLV-1), a retrovirus that primarily infects CD4+ T cells and causes lifelong infection, develop HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Current treatments...
8.
Yamagishi M
Int J Hematol
. 2022 Oct;
116(6):828-836.
PMID: 36239901
Malignant lymphomas are a group of diseases with epigenomic abnormalities fundamental to pathogenesis and pathophysiology. They are characterized by a high frequency of abnormalities related to DNA methylation regulators (DNMT3A,...
9.
Yamagishi M
Rinsho Ketsueki
. 2022 Oct;
63(9):1157-1166.
PMID: 36198541
Malignant lymphomas are a group of diseases in which epigenomic abnormalities are fundamental to the pathogenesis and pathophysiology and are characterized by a high frequency of abnormalities in DNA methylation...
10.
Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, et al.
Liver Int
. 2022 Jul;
42(10):2329-2340.
PMID: 35833881
Background And Aims: Although KRAS mutations are the major driver of intrahepatic cholangiocarcinoma (ICC), their role remains unexplored. This study aimed to elucidate the prognostic effects, association with clinicopathologic characteristics...